CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 314 enrolled
Drug / intervention
Febuxostat +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01078389
NCT01078389Phase 2Completed
CompareCT.gov

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo in Joint Damage in Hyperuricemic Subjects With Early Gout

Takeda·interventional·Posted Mar 2, 2010·Updated Sep 10, 2014

In Brief

A Phase 2 clinical trial evaluating Febuxostat and Placebo for Febuxostat for Joint Damage. Completed, enrolled 314 participants across 56 sites.

Detailed Summary

This purpose of this study is to assess the effect of febuxostat, once daily (QD), on joint damage in patients with elevated serum urate levels and gout.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJoint Damage
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2, 2010
Enrollment StartMar 1, 2010
Primary CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 16.3 years ago

Interventions

Febuxostatdrug

Febuxostat capsules

Placebo for Febuxostatdrug

Febuxostat placebo-matching capsules